Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKE | Q14164 | 1/20 | 0.32 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8401988 | 0.79 | ALOX15 (0.33) | ALDH1A1 | |
| SCHEMBL12972229 | 0.75 | — | — | |
| SCHEMBL27181958 | 0.74 | SMN1; SMN2 (0.33) | IKBKETBK1NPC1MAPK1RAB9A | |
| SCHEMBL27181960 | 0.74 | SMN1; SMN2 (0.33) | IKBKETBK1NPC1MAPK1RAB9A | |
| SCHEMBL15548316 | 0.74 | TSHR (0.36) | IKBKETBK1MEN1NPC1MAPK1 | |
| SCHEMBL13325881 | 0.72 | CALM1 (0.34) | MEN1NPC1MAPK1CASP1RAB9A | |
| SCHEMBL30984508 | 0.71 | — | — | |
| Boric Acid SCHEMBL22284324 | 0.70 | — | — | |
| SCHEMBL617047 | 0.69 | — | — | |
| SCHEMBL14779490 | 0.69 | POLB (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE41366-E1 | Total synthesis of galanthamine, analogues and derivatives thereof | CENTRE NATIONAL DEL LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-06-01 | — | — | US | claimed |
| EP-1458724-B1 | TOTAL SYNTHESIS OF GALANTHAMINE, ANALOGUES AND DERIVATIVES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2007-08-15 | — | — | EP | claimed |
| US-7109327-B2 | Oxidizing agent mixed with a support starting from 8-methoxy-3,4,4a,8a-tetrahydro-spiro-chromen-2-one-[4,4']-cyclohex-2',5'-dien-1'-one to a spirodienone yields 1.6 (+-)-11-oxonarwedine or (+-)-6-methoxy-10-methyl-galantham-1-ene-3,11-dione; treating Alzheimer's disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2006-09-19 | — | — | US | claimed |
| US-20050065338-A1 | Total synthesis of galanthamine, analogues and derivatives thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2005-03-24 | — | — | US | claimed |
| US-RE41366-E1 | Total synthesis of galanthamine, analogues and derivatives thereof | CENTRE NATIONAL DEL LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-06-01 | — | — | US | disclosed |
| US-RE41366-E1 | Total synthesis of galanthamine, analogues and derivatives thereof | CENTRE NATIONAL DEL LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-06-01 | — | — | US | disclosed |
| US-RE41366-E1 | Total synthesis of galanthamine, analogues and derivatives thereof | CENTRE NATIONAL DEL LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-06-01 | — | — | US | disclosed |
| EP-1458724-B1 | TOTAL SYNTHESIS OF GALANTHAMINE, ANALOGUES AND DERIVATIVES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2007-08-15 | — | — | EP | disclosed |
| EP-1458724-B1 | TOTAL SYNTHESIS OF GALANTHAMINE, ANALOGUES AND DERIVATIVES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2007-08-15 | — | — | EP | disclosed |
| US-7109327-B2 | Oxidizing agent mixed with a support starting from 8-methoxy-3,4,4a,8a-tetrahydro-spiro-chromen-2-one-[4,4']-cyclohex-2',5'-dien-1'-one to a spirodienone yields 1.6 (+-)-11-oxonarwedine or (+-)-6-methoxy-10-methyl-galantham-1-ene-3,11-dione; treating Alzheimer's disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2006-09-19 | — | — | US | disclosed |
| US-20050065338-A1 | Total synthesis of galanthamine, analogues and derivatives thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2005-03-24 | — | — | US | disclosed |
| EP-1458724-A1 | TOTAL SYNTHESIS OF GALANTHAMINE, ANALOGUES AND DERIVATIVES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2004-09-22 | — | — | EP | disclosed |
| WO-2002102803-A1 | TOTAL SYNTHESIS OF GALANTHAMINE, ANALOGUES AND DERIVATIVES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065338-A1 | Total synthesis of galanthamine, analogues and derivatives thereof | GALR1, GALR3, GALR2 | IKBKE 4751/4885TBK1 4452/4885MEN1 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.